Rudolf de BOER

Rudolph de Boer

Rudolf de Boer (1972, Gouda, the Netherlands) is a Clinical Cardiologist, a Full Professor of Translational Cardiology, and the Director of the Experimental Cardiology at the University Medical Center Groningen, the Netherlands (https://www.groningencardiology.com).
He studied medicine at the University of Groningen, completed research fellowships at the University of Utah, the University of Groningen, and at Harvard Medical School.
His research group focuses on cardiac remodeling and heart failure, fibrosis, diabetes, and cardio-oncology, always trying to connect clinical observations to preclinical and mechanistic studies. The last years he has studied biomarkers in clinical heart failure and in the general population, and focused on their role in the pathophysiology. Recently he focused on the interaction of heart failure and co-morbidities, especially cancer. He has been was a founding member the scientific committee of LifeLines, a population study of 165,000 subjects. Doctor de Boer’s clinical interests are cardiogenetics, echocardiography and end-stage heart failure including VAD therapy and transplant.
De Boer has authored and co-authored over 450 articles in peer reviewed journals (https://www.ncbi.nlm.nih.gov/pubmed/?term=de+boer+ra) and wrote over 10 book chapters. He received grants from the Netherlands Heart Foundation, the Dutch Organization for Scientific Research, and the European research Council (ERC).
De Boer is the current President-Elect of the Dutch Cardiac Society. He was appointed a Fellow of the European Society of Cardiology (ESC) in 2010. He was president of the Heart Failure Working Group of the Dutch Society of Cardiology from 2014-2019, and has been a Board Member of the Heart Failure Association (HFA) of the ESC from 2014-2020, where he coordinated the HFA committee on Heart Failure with Preserved Ejection Fraction (HFpEF), was member of the study groups of biomarkers, cardio-oncology, and the Translational Committee. He has been member of the ESC Education, Advocacy, and eHealth committees. In 2020, he joined the ESC council of Cardio-oncology as Liaison Officer.
Dr. de Boer has been Associate Editor of the European Journal of Heart Failure from 2009-2020, and since 2020 is associate editor of European Heart Journal (section heart failure), as well as being ad-hoc reviewer for several journals, including Circulation, Journal of the American College of Cardiology, and the European Heart Journal.